S0758

Sulfaphenazole

Name: Sulfaphenazole
Brand: SIGMA
Price: 1935 ILS

≥98%, CYP2C9 inhibitor, powder

Synonym(s):

4-Amino-N-(1-phenyl-1H-pyrazol-5-yl)benzenesulfonamide

Slide 1 of 2

Select a Size

1 G

₪1,935.00

5 X 1 G

₪7,057.00

₪1,935.00

Please contact Customer Service for Availability

About This Item

Empirical Formula (Hill Notation):

C₁₅H₁₄N₄O₂S

CAS Number:

526-08-9

Molecular Weight:

314.36

NACRES:

NA.77

PubChem Substance ID:

24278198

UNSPSC Code:

12352204

EC Number:

208-384-3

MDL number:

MFCD00057226

Key Documents

View All Documentation

Product Name

Sulfaphenazole, ≥98%

InChI key

QWCJHSGMANYXCW-UHFFFAOYSA-N

InChI

1S/C15H14N4O2S/c16-12-6-8-14(9-7-12)22(20,21)18-15-10-11-17-19(15)13-4-2-1-3-5-13/h1-11,18H,16H2

SMILES string

Nc1ccc(cc1)S(=O)(=O)Nc2ccnn2-c3ccccc3

assay

≥98%

form

powder

solubility

ethanol: 25 mg/mL, clear, colorless to yellow

storage temp.

2-8°C

Quality Level

100

Gene Information

human ... CYP2C18(1562), CYP2C19(1557), CYP2C9(1559)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Bioactive Small Molecule Inhibitors

Bioactive Small Molecules

Compare Similar Items

View Full Comparison

Show Differences

1 of 4

This Item	SML1061	SML1060	SML1693
Sigma-Aldrich S0758 Sulfaphenazole	Sigma-Aldrich SML1061 PF-04856264	Sigma-Aldrich SML1060 Celecoxib-NBD	Sigma-Aldrich SML1693 Pz-1
assay ≥98%	assay ≥98% (HPLC)	assay ≥98% (HPLC)	assay ≥98% (HPLC)
Gene Information human ... CYP2C18(1562), CYP2C19(1557), CYP2C9(1559)	Gene Information -	Gene Information -	Gene Information -
Quality Level 100	Quality Level 100	Quality Level 100	Quality Level 100
form powder	form powder	form powder	form powder
storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C	storage temp. 2-8°C
solubility ethanol: 25 mg/mL, clear, colorless to yellow	solubility DMSO: 10 mg/mL, clear	solubility DMSO: 10 mg/mL, clear	solubility DMSO: 1 mg/mL, clear (warmed)

Application

Sulfaphenazole has been used as a positive control to inhibit cytochrome P450 2C9 (cyp2c9) to quantify Rhodiola rosea inhibition.[1] It has also been used as cytochrome P450 2C9 (cyp2c9) inhibitor in endothelial cells[2] and microsomal preparations.[3]

Biochem/physiol Actions

Antibacterial. Specific inhibitor of CYP2C9. Blocks pro-inflammatory and atherogenic effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Specific inhibitor of CYP2C9. Blocks pro-inflammatory and atherogenic effects of linoleic acid (increase in oxidative stress and activation of AP-1) mediated by CYP2C9. Inhibits bradykinin-induced tPA release.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

0000508715

0000436070

0000368519

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform

Moraes CB, et al.

SLAS discovery, 24(3), 346-361 (2019)

Noncompetitive inhibition of human CYP 2C9 in vitro by a commercial Rhodiola rosea product

Thu OKF, et al.

Pharmacology Research & Perspectives, 5(4), e00324-e00324 (2017)

Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity.

Ralf Heim et al.

Journal of medicinal chemistry, 51(16), 5064-5074 (2008-08-05)

Recently, we reported on the development of potent and selective inhibitors of aldosterone synthase (CYP11B2) for the treatment of congestive heart failure and myocardial fibrosis. A major drawback of these nonsteroidal compounds was a strong inhibition of the hepatic drug-metabolizing

Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives.

Simon Lucas et al.

Journal of medicinal chemistry, 54(7), 2307-2319 (2011-03-10)

Pyridine substituted 3,4-dihydro-1H-quinolin-2-ones (e.g., 1-3) constitute a class of highly potent and selective inhibitors of aldosterone synthase (CYP11B2), a promising target for the treatment of hyperaldosteronism, congestive heart failure, and myocardial fibrosis. Among these, ethyl-substituted 3 possesses high selectivity against

Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes.

Zhiping Jin et al.

Basic & clinical pharmacology & toxicology, 130(5), 592-605 (2022-03-16)

Anlotinib is a small molecule of novel tyrosine kinase inhibitor initially approved to treat non-small cell lung cancer in China. Drug-drug interaction (DDI) is an extrinsic factor important for the appropriate use of anlotinib in clinical practice. In vitro experiments

View All Related Papers

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service

Sulfaphenazole